Prevalence and diagnostic implications of anti-citrullinated peptide antibody in smear-positive pulmonary tuberculosis patients
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260237Keywords:
Smear-positive tuberculosis, Pulmonary tuberculosis, Diagnostic implications, Autoantibodies, Anti-citrullinated peptide antibodyAbstract
Background: Generation of autoantibodies have been described in several infectious diseases including tuberculosis. Rheumatoid arthritis-specific autoantibodies: anti-citrullinated protein antibody presents in pulmonary tuberculosis, patient without evidence of cross-reactivity in tuberculosis bacilli antigens. To evaluate prevalence of ACPA positivity and its association with sputum smear acid-fast bacilli (AFB) grading in pulmonary tuberculosis patients with positive smear.
Methods: This descriptive, observational study was carried out during June 2020 to July 2021 at the Department of Rheumatology, Bangladesh Medical University and National Institute of Diseases of Chest and Hospital Dhaka. One hundred adult, smear-positive pulmonary tuberculosis (TB) patients were recruited by consecutive sampling. Levels of serum ACPA were detected by ELISA. Sociodemographic, clinical and laboratory measures were described with descriptive statistics and compared by chi-square tests.
Results: Positivity of ACPAs was found in 28.0% of patients, with 12.0% showing high levels of ACPA (>60 IU/ml). The median value in the serum ACPA positive patients was 66.0 IU/ml (IQR: 48.5–88.0). Positive-ACPA was also slightly more common in patients with sputum smear grade of 2+ to 3+ compared to that of the lower smearing grades, but without statistical significance (p=0.821).
Conclusions: A significant proportion of smear-positive pulmonary tuberculosis cases showed positivity to ACPA. These results indicated that ACPAs should be interpreted with caution in tuberculosis-endemic regions to prevent the misdiagnosis of inflammatory arthritis.
Metrics
References
World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization. 2023.
Hossain S, Quaiyum MA, Zaman K, Banu S, Husain MA. Tuberculosis control in Bangladesh: progress, challenges and future directions. J Infect Public Health. 2020;13(7):973–81.
Elkayam O, Yaron M, Caspi D. Tuberculosis and autoimmune diseases. Autoimmun Rev. 2006;5(3):174–8.
Kroot EJ, Hazes JM, Colin EM, Dolhain RJ, van Leeuwen MA, van Rijswijk MH, et al. Rheumatoid factor, anti-citrullinated peptide antibodies and prognosis in rheumatoid arthritis. Ann Rheum Dis. 2000;59(11):884–9.
van der Helm-van Mil AH, Huizinga TW, de Vries RR, Toes RE. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum. 2005;52(6):1728–35. DOI: https://doi.org/10.1002/art.22716
Yamada R, Suzuki A, Chang X, Yamamoto K. Anti-citrullinated protein antibody production is enhanced in chronic infectious diseases. Rheumatology (Oxford). 2007;46(8):1179–83.
Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with uncitrullinated peptides. Arthritis Rheum. 2009;60(6):1576–81.
Singal R, Goyal S, Sharma S, Singla P. Autoantibody profile in patients with active pulmonary tuberculosis. Int J Rheum Dis. 2013;16(5):546–9.
Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57–72. DOI: https://doi.org/10.1016/S0140-6736(10)62173-3
Elkayam O, Gat A, Lidgi M, Segal R, Yaron M, Caspi D. Atypical cutaneous findings in a patient with systemic lupus erythematosus. Lupus. 2003;12(6):413–7. DOI: https://doi.org/10.1191/0961203303lu376cr
Mori S, Naito H, Ohtani S, Yamanaka T, Sugimoto M. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis. Clin Rheumatol. 2009;28(3):277–83. DOI: https://doi.org/10.1007/s10067-008-1035-5
Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52(11):3433–8. DOI: https://doi.org/10.1002/art.21385
Cha S, Choi CB, Han TU, Kang CP, Kang C, Bae SC. Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis Rheum. 2007;56(5):1454–63. DOI: https://doi.org/10.1002/art.22570
García-Berrocal B, González C, Pérez M, Navajo JA, Moreta I, Dávila C, et al. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients. Clin Chim Acta. 2005;354(1–2):123–30. DOI: https://doi.org/10.1016/j.cccn.2004.11.025
Makrygiannakis D, af Klint E, Lundberg IE, Löfberg R, Ulfgren AK, Klareskog L, et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis. 2006;65(9):1219–22. DOI: https://doi.org/10.1136/ard.2005.049403
Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008;58(6):1576–81. DOI: https://doi.org/10.1002/art.23514
Lima I, Santiago M. Antibodies against cyclic citrullinated peptides in infectious diseases: a systematic review. Clin Rheumatol. 2010;29(12):1345–51. DOI: https://doi.org/10.1007/s10067-010-1544-x
Hayashi N, Kawamoto T, Mukai M, Morinobu A, Koshiba M, Kondo S, et al. Detection of antinuclear antibodies by enzyme immunoassay using nuclear HEp-2 cell extract and recombinant antigens: comparison with immunofluorescence assay. Clin Chem. 2001;47(9):1649–59. DOI: https://doi.org/10.1093/clinchem/47.9.1649
Downloads
Published
How to Cite
Issue
Section
